Advertisement
News
Advertisement

Mylan Recalls 10 Lots of Etomidate Injection

Fri, 02/14/2014 - 1:26pm

Mylan has announced that its subsidiary Agila Specialties Private Limited is conducting a voluntary nationwide recall to the hospital/user level of 10 lots of Etomidate Injection 2 mg/mL - 10 mL and 20 mL (see lot breakdown below). The 10 lots were manufactured by Agila Specialties Polska sp.zo.o in Warsaw, Poland.  All of the products bear a Pfizer label. Agila Specialties Private Limited initiated the recall on Feb. 13, 2014, due to the potential for small black particles, identified as paper shipper labels, to be present in individual vials; the potential for missing lot number and/or expiry date on the outer carton, and the potential for illegible/missing lot number and expiry on individual vials.  Intravenous administration of particles may lead to impairment of microcirculation, phlebitis, infection, embolism and subsequent infarction.  Mylan and Pfizer have not received any reports of adverse events related to the recalled product to date.  

Etomidate is a hypnotic drug without analgesic activity. It is indicated by intravenous injection for the induction of general anesthesia. Etomidate is also indicated for the supplementation of subpotent anesthetic agents. Etomidate 2 mg/mL is packaged in glass vials in 10 mL and 20 mL volumes. Product was distributed Nationwide to distributors, retailers, hospitals, pharmacies, and/or clinics. The affected Etomidate lots include the following:

 

Etomidate Injection 2 mg/mL

NDC

Size

Lot #

Expiration

0069-0006-03

20  mL

5001012

Sep-14

   

5000927

Jun-14

   

5000931

Jun-14

   

5000936

Jun-14

   

5000942

Jun-14

   

5001071

Oct-14

   

5001040

Sep-14

0069-0006-01

10 mL

5001023

Sep-14

   

5000983

Aug-14

   

5000986

Aug-14

 

Mylan notified its customers of the recall by letter on Feb. 13, 2014. Distributors, retailers, hospitals, pharmacies, or clinics that have product which is being recalled should stop use and discontinue distribution.

Consumers with questions regarding this recall can contact Mylan Customer Service with questions at 800.848.0462 on Monday through Friday between 8 a.m. and 5 p.m. EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm          

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading